CG Oncology (CGON) Net Income towards Common Stockholders (2023 - 2025)
Historic Net Income towards Common Stockholders for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$43.7 million.
- CG Oncology's Net Income towards Common Stockholders fell 11420.24% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 9228.62%. This contributed to the annual value of -$88.0 million for FY2024, which is 2985.49% down from last year.
- As of Q3 2025, CG Oncology's Net Income towards Common Stockholders stood at -$43.7 million, which was down 11420.24% from -$41.4 million recorded in Q2 2025.
- In the past 5 years, CG Oncology's Net Income towards Common Stockholders registered a high of -$12.4 million during Q1 2023, and its lowest value of -$43.7 million during Q3 2025.
- Moreover, its 3-year median value for Net Income towards Common Stockholders was -$20.4 million (2024), whereas its average is -$25.0 million.
- Per our database at Business Quant, CG Oncology's Net Income towards Common Stockholders plummeted by 1650.68% in 2024 and then plummeted by 11914.08% in 2025.
- CG Oncology's Net Income towards Common Stockholders (Quarter) stood at -$22.5 million in 2023, then plummeted by 41.39% to -$31.8 million in 2024, then tumbled by 37.46% to -$43.7 million in 2025.
- Its last three reported values are -$43.7 million in Q3 2025, -$41.4 million for Q2 2025, and -$34.5 million during Q1 2025.